The global market for ovarian cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of ovarian cancer patients.
Key players in the Global Ovarian Cancer Diagnostics Market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on ovarian cancer patients. Such cooperative efforts are of paramount importance in the global ovarian cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.
Request a Free Sample Report Here - https://www.factmr.com/connectus/sample?flag=S&rep_id=51
Ovarian cancer is developed by uncontrollable growth of cells in ovaries. Made up of three different types of cells, ovaries may develop three different types of tumors. Majority of these tumors are non-cancerous, which can be treated by removing either part of the ovary containing the tumor, or by removing the ovary itself.
The American Cancer Society estimates that approx. 20,000 women will be diagnosed with ovarian cancer in the U.S. and more than 14,000 will lose their lives because of it in 2017 alone. In terms of deaths, this form of cancer ranks fifth and it led to more deaths than any other female reproductive system form of cancer. The chance of a women developing ovarian cancer during her life is 1 in 75 and the chance of her dying is 1 in 100. It is mainly seen in older women above the age of 63 years. Even though the rate at which women have been diagnosed with ovarian cancer has been falling, it is still a public health menace that needs to be tackled effectively. This is where the ovarian cancer diagnostics market can play a crucial role. The global ovarian cancer diagnostics market is predicted to grow with a CAGR of 8.7% and be worth nearly US$ 1 billion in 2022, from less than US$ 640 million in 2017.
The Epithelial Tumors Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself. North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumors segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study. Even the stromal carcinoma tumors segment is marginal at best when contrasted with epithelial tumors in the ovarian cancer diagnostics market. The stromal carcinoma tumors segment is likely to be valued at only US$ 28 million in 2017.
The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022. Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017. While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.
View Full Report Here - https://www.factmr.com/report/51/ovarian-cancer-diagnostics-market
The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.
Competition Tracking
The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.
Table of Contents
Chapter 1. Global Ovarian Cancer Diagnostics Market - Executive Summary. 26
Chapter 2. Global Ovarian Cancer Diagnostics Market Overview. 28
2.1. Introduction. 28
2.1.1. Global Ovarian Cancer Diagnostics Market Taxonomy. 28
2.1.2. Global Ovarian Cancer Diagnostics Market Definition. 28
2.2. Global Ovarian Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 28
2.2.1. Global Ovarian Cancer Diagnostics Market Y-o-Y Growth. 28
2.3. Global Ovarian Cancer Diagnostics Market Dynamics. 29
2.3.1. Drivers. 29
2.3.2. Restraints. 29
2.3.3. Trends. 29
2.4. Supply Chain. 30
2.5. Epidemiology. 30
2.6. List of Distributors. 30
2.7. Average Pricing Analysis. 30
2.8. Regulations. 30
2.9. Key Participants Market Presence (Intensity Map) By Region. 31
Chapter 3. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Cancer Type. 32
3.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By Cancer Type, 2012-2022. 32
3.1.1. Epithelial Tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 32
3.1.1.2. Market Share Comparison, By Region. 34
3.1.1.3. Y-o-Y growth Comparison, By Region. 34
Continued………………………..
If You Need This Useful Report Then Buy This Report Here - https://www.factmr.com/checkout/945/S
About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.
Contact Us -
FactMR
Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593
Email: [email protected]
Website: https://www.factmr.com/
